Daytrana Duration-Of-Use Data Suggest Potential For Individualized Dosing
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase IIIb study of methylphenidate patch shows efficacy when used for four- and six-hour periods, Shire says.
You may also be interested in...
Shire/Noven Daytrana Patch To Carry Similar Warnings To Other ADHD Drugs, FDA Says
The transdermal methylphenidate patch is approved with one additional warning relating to skin reactions and possible sensitivity to oral methylphenidate products.
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
Teva To Investigate High-Dose Copaxone
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.